financetom
Business
financetom
/
Business
/
MarketAxess Average Daily Volume Rises in November vs Year Ago
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MarketAxess Average Daily Volume Rises in November vs Year Ago
Dec 4, 2024 6:12 AM

08:37 AM EST, 12/04/2024 (MT Newswires) -- MarketAxess Holdings ( MKTX ) said Wednesday its total average daily volume came in at $44.95 billion in November, up 56% from a year earlier but down 3% compared to October.

Total rates ADV was $30.7 billion in November, up 112% from a year ago, but down 2% compared to October, the company said.

High-grade credit ADV was $6.53 billion in November, compared with $6.52 billion a year earlier, while high-yield credit ADV was $1.31 billion last month, compared to $1.91 billion a year ago, the company said.

MarketAxess ( MKTX ) shares fell more than 3% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing to brief European regulators on new production plans after 737 MAX panel blowout
Boeing to brief European regulators on new production plans after 737 MAX panel blowout
Jun 27, 2024
SEATTLE, June 27 (Reuters) - Boeing ( BA ) is planning a briefing for high-level European regulatory officials about changes to the way it makes planes, a senior company executive said, after a January mid-air panel blowout sparked a safety crisis. Boeing ( BA ) has been under pressure over factory controls since Jan. 5, when a door plug tore...
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
Jun 27, 2024
05:02 AM EDT, 06/27/2024 (MT Newswires) -- Genmab A/S ( GMAB ) said late Wednesday that the US Food and Drug Administration approved Epkinly, or epcoritamab-bysp, for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication has been given the green signal under the FDA's accelerated approval program based...
Drugmaker Servier loses EU court fight over pay-for-delay deals
Drugmaker Servier loses EU court fight over pay-for-delay deals
Jun 27, 2024
BRUSSELS (Reuters) -French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva, Unichem and its subsidiary Niche, Matrix which is...
Update: Levi Strauss Fiscal Q2 Earnings Beat But Sales Lag Forecast; Shares Sink Premarket
Update: Levi Strauss Fiscal Q2 Earnings Beat But Sales Lag Forecast; Shares Sink Premarket
Jun 27, 2024
05:19 AM EDT, 06/27/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Levi Strauss (LEVI) shares extended declines in pre-market activity on Thursday to more than 15% after the company reported overnight a sales miss in fiscal Q2, taking the shine out of its earnings beat. The company reported fiscal Q2 adjusted earnings...
Copyright 2023-2026 - www.financetom.com All Rights Reserved